MX2022015733A - Formulacion estable para el anticuerpo monoclonal anti-pd-1 recombinante. - Google Patents

Formulacion estable para el anticuerpo monoclonal anti-pd-1 recombinante.

Info

Publication number
MX2022015733A
MX2022015733A MX2022015733A MX2022015733A MX2022015733A MX 2022015733 A MX2022015733 A MX 2022015733A MX 2022015733 A MX2022015733 A MX 2022015733A MX 2022015733 A MX2022015733 A MX 2022015733A MX 2022015733 A MX2022015733 A MX 2022015733A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
stable formulation
recombinant anti
antibody
recombinant
Prior art date
Application number
MX2022015733A
Other languages
English (en)
Inventor
Ping Hu
Yan Liu
Chunyun Sun
Qingru Huai
Shaomei Tian
Mingzhen Tao
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of MX2022015733A publication Critical patent/MX2022015733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una formulación estable para un anticuerpo monoclonal recombinante que consiste de un anticuerpo monoclonal anti-PD-1 recombinante, un amortiguador, un regulador de la presión osmótica, un estabilizador y un tensioactivo. La formulación farmacéutica puede intensificar la estabilidad del anticuerpo y prolongar un período de validez en las formulaciones acuosas.
MX2022015733A 2020-06-19 2021-06-17 Formulacion estable para el anticuerpo monoclonal anti-pd-1 recombinante. MX2022015733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010566153 2020-06-19
PCT/CN2021/100658 WO2021254447A1 (zh) 2020-06-19 2021-06-17 一种重组抗pd-1单克隆抗体的稳定制剂

Publications (1)

Publication Number Publication Date
MX2022015733A true MX2022015733A (es) 2023-01-18

Family

ID=79268518

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015733A MX2022015733A (es) 2020-06-19 2021-06-17 Formulacion estable para el anticuerpo monoclonal anti-pd-1 recombinante.

Country Status (10)

Country Link
US (1) US20230272106A1 (es)
EP (1) EP4169530A4 (es)
JP (1) JP7523595B2 (es)
KR (1) KR20230026446A (es)
CN (1) CN115484983B (es)
AU (1) AU2021292116A1 (es)
BR (1) BR112022025721A2 (es)
CA (1) CA3180463A1 (es)
MX (1) MX2022015733A (es)
WO (1) WO2021254447A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6949718B2 (ja) * 2015-04-17 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物
CN106390115A (zh) * 2015-07-29 2017-02-15 上海君实生物医药科技股份有限公司 一种人源化单克隆抗体的稳定制剂
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
EP3842070A4 (en) * 2018-07-18 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MEDICATED COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
CA3118144A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途
CN109498565B (zh) * 2018-12-27 2021-06-29 兴盟生物医药(苏州)有限公司 一种稳定的抗pd-1抗体制剂及其用途
CN110787292B (zh) * 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途

Also Published As

Publication number Publication date
AU2021292116A1 (en) 2023-01-05
BR112022025721A2 (pt) 2023-01-03
CA3180463A1 (en) 2021-12-23
WO2021254447A1 (zh) 2021-12-23
US20230272106A1 (en) 2023-08-31
JP7523595B2 (ja) 2024-07-26
CN115484983A (zh) 2022-12-16
JP2023529234A (ja) 2023-07-07
EP4169530A4 (en) 2024-07-17
KR20230026446A (ko) 2023-02-24
EP4169530A1 (en) 2023-04-26
CN115484983B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
PH12019502123A1 (en) Stable antibody formulation
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
AU2019339740A8 (en) CSF-1R antibody formulation
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
CL2020002252A1 (es) Formulación oftálmica.
UY38153A (es) Formulaciones acuosas estables de anticuerpos anti-tau
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
JOP20210229A1 (ar) صيغة جسم مضاد علاجي
MX2021011137A (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33.
MX2023014616A (es) Formulaciones de anticuerpos anti-pd1.
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
CL2023000486A1 (es) Formulación farmacéutica que comprende un bite, anticuerpo biespecífico y metionina
BR112022012768A2 (pt) Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma
MX2022015733A (es) Formulacion estable para el anticuerpo monoclonal anti-pd-1 recombinante.
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
MX2021007047A (es) Formulaciones de anticuerpos.
MX2022010217A (es) Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
CO2020013545A2 (es) Formulación estable de anticuerpos
BR112022022919A2 (pt) Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".
MX2024000829A (es) Proteinas actrii y usos de las mismas.
AU2016204324A1 (en) Antibody formulation
UY37260A (es) Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón